Yellow Fever

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Yellow Fever is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • Bunyavirus Infection

Disorder Subdivisions

  • None

General Discussion

Yellow Fever is a viral infection that causes damage to the liver, kidney, heart and gastrointestinal tract. Major symptoms may include sudden onset of fever, yellowing of the skin (jaundice) and hemorrhage. It occurs predominately in South America, the Caribbean Islands and Africa. The disease is spread through bites of infected mosquitos. Incidence of the disease tends to increase in the summer as the mosquito population increases, and it occurs year round in tropical climates.

Yellow Fever has two cycles: the sylvan cycle in which mosquitos primarily spread the disease among forest-dwelling primates, and the urban cycle in which the infection is spread from human to human.


The symptoms of Yellow Fever are the sudden onset of fever and chills along with headache, backache, generalized pain, nausea, vomiting, flushed face and infection of the inner eyelid. The fever usually disappears after three days, reappearing several days later with new symptoms of jaundice, bleeding gums, soft palate hemorrhages, and the vomiting of blood (black vomit). The patient may go into shock during this phase.

Yellow Fever may also appear in a mild form with symptoms resembling influenza, malaria, dengue fever or typhoid. In this case, the fever usually lasts less than one week.


Yellow Fever is caused by a virus spread by the bite by an infected mosquito. Initially, a mosquito acquires the disease by ingesting the blood of an infected host. The mosquito then transmits the infection to its next bite victim.

Affected Populations

Yellow Fever affects males and females equally. People living in semitropical or tropical climates are at risk unless they are vaccinated against this infection. People in southern areas of the United States, living near marshes and swamps may be at risk during the summer months. However, most cases of Yellow Fever occur in Africa and South America.

Standard Therapies

The treatment of Yellow Fever is symptomatic and supportive. Preventative measures consist of mosquito control and a vaccine that prevents development of the infection. Immunity from a vaccination usually develops after 10 days and lasts for more than 10 years. In some cases, side effects associated with vaccination may occur five to 10 days later. These side effects affect approximately 5 percent of individuals receiving immunization and may include headache, fever, and/or aching muscles.

Investigational Therapies

Information on current clinical trials is posted on the Internet at All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, contact:



Internal Medicine, 2nd Ed.: Jay H. Stein, ed.-in-chief; Little, Brown and Co., 1987. Pp. 1594-1599.

The Merck Manual, Volume 1, 14th Ed.: Robert Berkow, M.D. ed.-in chief; Merck, Sharp & Dohme Laboratories., 1982. Pp. 120.


Fournier-Caruana J, et al., In vitro potency assay for yellow fever vaccines: comparison of three vero cell lines sources. Biologicals. 2000;28:33-40.

Perraut R, et al., Stability-related studies on 17D yellow fever vaccine. Microbes Infect. 2000;2:33-8.

Tomori O, Impact of yellow fever on the developing world. Adv Virus Res. 1999;53:5-34.

Monath TO, Yellow fever: a medically neglected disease. Report on a seminar. Rev Infect Dis. 1987;9:165-75.

de Souza Lopes O, et al., Studies on yellow fever vaccine. I. Quality control parameters. J Biol Stand. 1987;159:323-9.


Centers for Disease Control and Prevention

1600 Clifton Road NE

Atlanta, GA 30333

Tel: (404)639-3534

Tel: (800)232-4636

TDD: (888)232-6348



NIH/National Institute of Allergy and Infectious Diseases

NIAID Office of Communications and Government Relations

5601 Fishers Lane, MSC 9806

Bethesda, MD 20892-9806

Tel: (301)496-5717

Fax: (301)402-3573

Tel: (866)284-4107

TDD: (800)877-8339



World Health Organization (WHO)

Avenue Appia 20

Geneva 27, 1211


Tel: 41227912111

Fax: 41227913111


Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223


For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see